171 related articles for article (PubMed ID: 11753266)
1. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Phimmasone S; Kharasch ED
Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
[TBL] [Abstract][Full Text] [Related]
2. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
3. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
Kharasch ED; Hoffer C; Walker A; Sheffels P
Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
5. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Ibrahim AE; Feldman J; Karim A; Kharasch ED
Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
[TBL] [Abstract][Full Text] [Related]
6. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Kharasch ED; Russell M; Mautz D; Thummel KE; Kunze KL; Bowdle A; Cox K
Anesthesiology; 1997 Jul; 87(1):36-50. PubMed ID: 9232132
[TBL] [Abstract][Full Text] [Related]
7. Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Baririan N; Van Obbergh L; Desager JP; Verbeeck RK; Wallemacq P; Starkel P; Horsmans Y
Clin Pharmacokinet; 2007; 46(3):261-70. PubMed ID: 17328584
[TBL] [Abstract][Full Text] [Related]
8. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimal and noninvasive probes for hepatic and first-pass CYP3A induction.
Kharasch ED; Francis A; London A; Frey K; Kim T; Blood J
Clin Pharmacol Ther; 2011 Jul; 90(1):100-8. PubMed ID: 21562488
[TBL] [Abstract][Full Text] [Related]
9. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
10. Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Kharasch ED; Whittington D; Hoffer C; Krudys K; Craig K; Vicini P; Sheffels P; Lalovic B
Clin Pharmacokinet; 2005; 44(7):731-51. PubMed ID: 15966756
[TBL] [Abstract][Full Text] [Related]
11. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
12. Alfentanil-induced miosis clearance as a liver CYP3A4 and 3A5 activity measure in healthy volunteers: improvement of experimental conditions.
Baririan N; Horsmans Y; Desager JP; Verbeeck R; Vanbinst R; Wallemacq P; Van Obbergh L
J Clin Pharmacol; 2005 Dec; 45(12):1434-41. PubMed ID: 16291719
[TBL] [Abstract][Full Text] [Related]
13. Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance.
Kharasch ED; Jubert C; Senn T; Bowdle TA; Thummel KE
J Clin Pharmacol; 1999 Jul; 39(7):664-9. PubMed ID: 10392320
[TBL] [Abstract][Full Text] [Related]
14. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
Kharasch ED; Whittington D; Hoffer C
Anesthesiology; 2004 Sep; 101(3):729-37. PubMed ID: 15329598
[TBL] [Abstract][Full Text] [Related]
15. Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
Kharasch ED; Vangveravong S; Buck N; London A; Kim T; Blood J; Mach RH
Clin Pharmacol Ther; 2011 Apr; 89(4):562-70. PubMed ID: 21346758
[TBL] [Abstract][Full Text] [Related]
16. Influence of CYP3A5 genotype on the pharmacokinetics and pharmacodynamics of the cytochrome P4503A probes alfentanil and midazolam.
Kharasch ED; Walker A; Isoherranen N; Hoffer C; Sheffels P; Thummel K; Whittington D; Ensign D
Clin Pharmacol Ther; 2007 Oct; 82(4):410-26. PubMed ID: 17554244
[TBL] [Abstract][Full Text] [Related]
17. Methadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.
Kharasch ED; Walker A; Whittington D; Hoffer C; Bedynek PS
Drug Alcohol Depend; 2009 May; 101(3):158-68. PubMed ID: 19232844
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.
Kharasch ED; Russell M; Garton K; Lentz G; Bowdle TA; Cox K
Anesthesiology; 1997 Jul; 87(1):26-35. PubMed ID: 9232131
[TBL] [Abstract][Full Text] [Related]
19. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice.
Veronese ML; Gillen LP; Burke JP; Dorval EP; Hauck WW; Pequignot E; Waldman SA; Greenberg HE
J Clin Pharmacol; 2003 Aug; 43(8):831-9. PubMed ID: 12953340
[TBL] [Abstract][Full Text] [Related]
20. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
